No Data
No Data
Haisco Pharmaceutical Group (002653.SZ) has gained approval to conduct clinical trials on the innovative drug HSK39004 inhalation suspension.
On July 25th, Geelong News reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the HSK39004 inhalation suspension, which was accepted in May 2024, meets the requirements for drug registration, and the clinical trial of the drug is approved. HSK39004 is a new targeted small molecule inhibitor with independent intellectual property rights independently developed by the company. It is clinically intended for the treatment of chronic obstructive pulmonary Disease. The preclinical research results show that HSK39004 has a good therapeutic effect on COPD in vitro.
Haisco Pharmaceutical Group's (SZSE:002653) Investors Will Be Pleased With Their Notable 82% Return Over the Last Five Years
Haisco Pharmaceutical Group (002653.SZ) has launched three phase III clinical trials for its hydroquinone project in the USA, two of which have been completed.
Haisco Pharmaceutical Group (002653.SZ) stated on the investor interaction platform on July 16 that the company has launched three Phase III clinical studies for its Hydroquinone project in the United States, two of which have been completed, and the other is progressing normally. The company is actively advancing related work and hoping to submit an NDA application to the FDA in the first half of 2025.
China Drug Regulator Accepts Haisco Pharma's Application for Injectible Pain Reliever
Haisco Pharmaceutical Expects to Double H1 Profit on Product Growth, Subsidies; Shares Up 4%
Haisco Pharmaceutical Group: 2024 Interim Performance Forecast
No Data